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index-adjusted BMD at the femoral neck and lumbar spine 
or bone loss at the 5.8-year follow-up. In logistic regression 
analysis, neither C. pneumoniae nor H. pylori IgG sero-
positivities predicted incident lumbar or spine osteoporosis 
5.8 years later. In conclusion, neither C. pneumoniae nor 
H. pylori IgG seropositivity was associated with bone turn-
over markers, the RANKL/OPG ratio, BMD, or bone loss 
in postmenopausal women. In addition, chronic infection 
with C. pneumoniae or H. pylori did not predict incident 
osteoporosis among this group of women.
Keywords Chlamydia pneumoniae · Helicobacter 
pylori · Bone mineral density · Osteoporosis
Introduction
Chlamydia pneumoniae is an obligate intracellular human 
respiratory pathogen that contributes to a wide spectrum of 
clinical presentations, including atherosclerosis [1]. This 
bacterium is able to survive in host cells and can affect 
chronic processes, such as atherosclerosis, through aug-
mentation of the inflammatory system, signaling pathways, 
and oxidative stress [2]. Thus, it is plausible to consider 
a contributory role for C. pneumoniae infection in accel-
erated bone loss. Indeed, in vitro and in vivo studies have 
shown that infection with C. pneumoniae produces poten-
tially inflammatory and bone resorptive cytokines and 
chemokines [3, 4]. Very recently, it has been reported that 
chlamydial DNA was found in osteoporotic bone tissue [5].
The association of Helicobacter pylori seropositivity 
with a variety of extradigestive manifestations, such as 
cardiovascular, immunological, and various other patholo-
gies, has been suggested [6]. However, the link between 
H. pylori and these extradigestive manifestations is 
Abstract The potential link between infection with Chla-
mydia pneumoniae or Helicobacter pylori and osteoporosis 
has not been investigated in population-based longitudinal 
studies. A total of 250 healthy postmenopausal women 
who participated in a prospective cohort study were evalu-
ated for IgG antibodies directed against C. pneumoniae and 
H. pylori, osteoprotegerin (OPG), the receptor activator of 
nuclear factor kappa B ligand (RANKL), CrossLaps, and 
osteocalcin. Bone mineral density (BMD) was measured at 
the femoral neck and lumbar spine at baseline and at fol-
low-up 5.8 years later. There were no significant differences 
in age-adjusted bone turnover markers, OPG, RANKL, 
the RANKL/OPG ratio, and BMD between the C. pneu-
moniae and H. pylori IgG seropositive and seronegative 
subjects (P > 0.05). Neither C. pneumoniae nor H. pylori 
IgG seropositivity was associated with age-and body mass 
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controversial [7]. There are also limited contradictory stud-
ies regarding the relationship between osteoporosis and 
infection with H. pylori [8–11]. Infection with H. pylori 
in children was not associated with significant changes in 
bone metabolism [8]. However, infection by CagA-positive 
H. pylori strains was more prevalent in osteoporotic men 
[9]. Reduced levels of estradiol and increased bone turno-
ver markers were also found in infected CagA-positive men 
with osteoporosis [9].
Given the contradictory data on the association between 
H. pylori infection and bone metabolism [8–11] and the 
very limited studies on C. pneumoniae infection and osteo-
porosis in humans [10], more studies are required to clarify 
the involvement of chronic infection with these organisms 
in bone health. The aim of this prospective, population-
based study was to evaluate the potential link between 
infections with H. pylori and C. pneumoniae and bone min-
eral density (BMD) in a sample of postmenopausal women.
Materials and methods
Community sampling
In an extension arm of the Iranian Multicentral Osteoporo-
sis Study, a community-based longitudinal study, an age-
stratified random sample of postmenopausal women was 
randomly selected from 13 clusters in Bushehr Port (the 
center of Bushehr province, which has the longest border 
with the Persian Gulf). All were community-dwelling and 
ambulatory. The following exclusion criteria were used: (1) 
the known presence of generalized bone diseases, including 
hyperparathyroidism, hypoparathyroidism, thyroid disor-
ders, rheumatoid arthritis, Cushing’s disease, and steroid-
induced osteoporosis, renal osteodystrophy, or other meta-
bolic diseases; (2) a history of malignant diseases and liver 
diseases; (3) drug addiction; and (4) restriction to bed rest 
within the last 2 weeks after an illness or complete bed rest 
for 3 months. The baseline examination took place 4 April 
to 22 September 2006, and the follow-up examination 
occurred at a median of 5.8 years. The study design was 
described previously in detail [12].
The participants in the current study were a subset of 
250 postmenopausal women who participated in the exten-
sion arm of the Iranian Multicentral Osteoporosis Study.
Physical examinations
A stadiometer was used to measure the subjects’ height and 
weight. Heavy outer garments and shoes were removed 
before the participants’ height and weight were measured. 
Their body mass index (BMI) was calculated. Waist cir-
cumference was defined at the midway level between the 
costal margins and the iliac crests. Hip circumference was 
measured at the level of the greater trochanters.
Bone mineral density (BMD) was determined for the 
lumbar spine (L2–L4) and proximal femur (neck) using 
dual-energy X-ray absorptiometry on an Osteocore II bone 
densitometer (Osteocore II Osteodensitometer; Medilink, 
France). To eliminate operator discrepancies, the same 
operator tested all the women during the study. Duplicate 
measurements were obtained from 30 women who agreed 
to undergo a repeat assessment on the same day, and the 
precision errors were calculated using the root mean square 
method. The coefficients of variation (CVs; precision) of 
the measurements of the lumbar spine and the femoral neck 
were 0.8 and 1.6 %, respectively.
Laboratory measurements
A fasting blood sample was taken. All the samples were 
promptly centrifuged and separated, and analyses were 
carried out at the Persian Gulf Health Research Center on 
the day of blood collection using a Selectra 2 autoanalyzer 
(Vital Scientific, Spankeren, The Netherlands).
IgG antibodies against C. pneumoniae were measured 
by a commercial test kit (DRG Instruments GmbH, Ger-
many). The kit is based on an indirect solid-phase enzyme 
immunoassay with horseradish peroxidase as a marker 
enzyme; the positivity threshold was enzyme immunou-
nits >45. Sera were screened for IgG antibodies against H. 
pylori with an ELISA kit (Radim SpA, Italy), and the sam-
ples were considered positive when IgG values were higher 
than 30 RU/mL for H. pylori.
Serum osteoprotegerin (OPG) levels were measured 
using an ELISA commercial kit (Biomedica Gruppe, 
Vienna, Austria). The detection limit of the assay was 
0.14 pmol/L. The mean intra-assay and interassay coef-
ficients of variation of the OPG assay were 4–10 % and 
7–8 %, respectively.
The receptor activator of nuclear factor-κB ligand 
(RANKL) levels was measured using an ELISA with an 
additional enhancement system (ampli-sRANKL; Bio-
medica Gruppe). The detection limit of the assay was 
0.4 pg/mL. The mean intra-assay and interassay CVs of the 
RANKL assay were 8–9 % and 6–3 %, respectively.
The N-MID osteocalcin ELISA (Nordic Bioscience 
Diagnostics A/S) was used for the quantitative measure-
ment of osteocalcin in sera. The intra-assay CVs for the 
low (7.0 ng/mL), medium (21.8 ng/mL), and high (43.2 ng/
mL) values were 3.4 %, 2.0 %, and 2.4 %, respectively.
The serum CrossLaps enzyme-linked immunosorb-
ent assay (Nordic Bioscience Diagnostics A/S, Herlev, 
Denmark) was used for the quantification of degradation 
products of C-terminal telopeptides of type I collagen in 
sera. The intra-assay CVs for low (0.242 ng/mL), medium 
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(0.375 ng/mL), and high (0.476 ng/mL) values were 5.4, 
5.0, and 5.1 %, respectively.
Serum alkaline phosphatase was determined by spec-
trophotometry using p-nitrophenylphosphate as substrate 
(ParsAzemon, Tehran, Iran). The intra-assay and interassay 
CVs were 1.5 % and 2.6 %, respectively.
Statistical methods
Normal distribution of the data was controlled with the 
Kolmogorov–Smirnov test. The significance of the differ-
ence in the results of any two groups was determined by 
Chi square analysis using 2 × 2 contingency tables for cat-
egorical variables. A two-tailed t test was used to compare 
the mean values across groups. We found that log trans-
formation of osteocalcin, CrossLaps, sRANKL, and OPG 
gave a better fit to a Gaussian distribution. The geometric 
mean for those biochemical variables was defined as the 
arithmetic mean of the log-transformed data ±SD, raised to 
the power of 10.
Annual bone loss was defined as the change in BMD 
between the initial and second BMD measures, divided by 
the time interval (year) between the baseline and follow-up 
measurements.
Multiple linear regression models were used to assess 
the association between BMD at a number of skeletal sites 
(or bone loss) and IgG seropositivities against C. pneumo-
niae or H. pylori. The models were adjusted for age and 
BMI as covariates.
Binary logistic regression was used to compute the rela-
tive risks of incident osteoporosis at any skeletal sites for 
individuals with C. pneumoniae or H. pylori infection, con-
trolled for age and BMI.
Probability values <5 % were considered statistically 
significant. All statistical analyses were performed using 
the PASW Statistics GradPack 18 (SPSS Inc., Chicago, IL).
Results
Table 1 shows the baseline characteristics of the studied 
postmenopausal women, stratified by IgG seropositivi-
ties against C. pneumoniae and H. pylori. The mean age 
(mean ± SD) of the women was 58.87 ± 8.02 years. The 
prevalence of IgG antibodies against C. pneumoniae and 
H. pylori among the studied population was 20.4 % (51 
women) and 57.2 % (143 women), respectively.
There were no significant differences in age, anthro-
pometric measures, bone turnover markers, markers of 
bone metabolism, and BMD between C. pneumoniae 
IgG seropositive and C. pneumoniae IgG seronegative 
subjects (Table 1, P > 0.05). Similar results were found 
Table 1  The baseline characteristics of the studied postmenopausal women, stratified by IgG seropositivities against C. pneumoniae and H. 
pylori
Data are given as means ± SD
BMD bone mineral density
a Receptor activator of nuclear factor-κB ligand
b Geometric mean ± SD
C. pneumoniae IgG H. pylori IgG
Positive Negative P value Positive Negative P value
Age, years 59.61 ± 8.78 58.68 ± 7.82 0.464 58.24 ± 7.55 59.88 ± 8.61 0.114
Waist circumference, cm 99.25 ± 12.34 99.19 ± 10.19 0.970 99.39 ± 9.90 98.95 ± 11.54 0.745
Body mass index, kg/m2 28.07 ± 5.23 28.32 ± 4.60 0.738 28.52 ± 4.57 27.93 ± 4.92 0.338
Waist-to-hip ratio 0.92 ± 0.08 0.92 ± 0.06 0.752 0.92 ± 0.06 0.92 ± 0.07 0.588
Osteoprotegerin, pmol/Lb 3.31 ± 1.82 3.66 ± 1.51 0.159 3.41 ± 1.58 3.84 ± 1.55 0.046
RANKL, pmol/Lab 1.62 ± 2.60 1.39 ± 3.27 0.409 1.41 ± 2.89 1.44 ± 3.51 0.916
RANKL/OPG ratio 0.41 ± 1.06 0.88 ± 1.04 0.330 0.75 ± 1.12 0.73 ± 1.05 0.899
Osteocalcin, ng/mLb 12.99 ± 2.23 11.62 ± 1.95 0.309 11.39 ± 1.76 12.62 ± 2.33 0.260
CrossLaps, ng/mLb 1.54 ± 1.65 1.72 ± 1.77 0.204 1.75 ± 1.69 1.59 ± 1.83 0.195
Alkaline phosphatase, U/L 242.41 ± 101.23 243.54 ± 94.76 0.940 237.86 ± 87.36 250.57 ± 107.53 0.307
Calcium, mg/dL 9.88 ± 0.46 9.82 ± 0.59 0.495 9.86 ± 0.54 9.79 ± 0.58 0.339
Phosphorus, mg/dL 3.90 ± 0.50 3.93 ± 0.50 0.680 3.92 ± 0.47 3.92 ± 0.53 0.979
Femoral neck BMD, g/cm2 0.837 ± 0.182 0.856 ± 0.201 0.534 0.874 ± 0.206 0.823 ± 0.183 0.046
Lumbar BMD, g/cm2 0.962 ± 0.230 0.951 ± 0.181 0.728 0.968 ± 0.184 0.931 ± 0.202 0.139
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when H. pylori IgG positive postmenopausal women 
were compared with H. pylori negative subjects, except 
for marginal significant differences in serum OPG levels 
and BMD a the femoral neck (Table 1, p > 0.05). How-
ever, these significant differences were lost by adjusting 
for age.
BMD at the lumbar spine and femoral neck decreased 
progressively with increases in age (P < 0.0001). Annual 
bone loss was 0.82 % at the femoral neck and 3.55 % at the 
lumbar spine among the women.
Cross‑sectional analysis
Neither C. pneumoniae nor H. pylori IgG seropositivi-
ties was associated with baseline age-adjusted and BMI-
adjusted BMD at the femoral neck and lumbar spine 
(Table 2). At baseline, according to the World Health 
Organization (WHO) criteria [13], 12 (4.8 %) and 16 
(6.4 %) women (9.2 %) were considered osteoporotic at 
the femoral neck and lumbar spine, respectively. C. pneu-
moniae and H. pylori infections were not associated with 
prevalent osteoporosis at the lumbar spine or the femoral 
neck (Table 3).
Prospective analysis
Baseline C. pneumoniae and H. pylori IgG seropositivities 
were not associated with age-adjusted and BMI-adjusted 
BMD at the femoral neck and lumbar spine during the 5.8-
year period (Table 2). During the 5.8-year follow-up period, 
19 (4.8 %) and 16 (6.4 %) women who were not osteoporo-
tic at baseline developed osteoporosis at the femoral neck 
and lumbar spine, respectively. In logistic regression analy-
sis, neither C. pneumoniae nor H. pylori IgG seropositivi-
ties predicted incident lumbar or spine osteoporosis after 
5.8 years (Table 3).
Discussion
We found that IgG seropositivities against C. pneumo-
niae and H. pylori were not associated with baseline bone 
metabolism and BMD at any skeletal sites among post-
menopausal women. Chronic infection with these organ-
isms was not involved in bone loss at 5.8-year follow-up. 
C. pneumoniae and H. pylori IgG seropositivities were 
not predictors of incident osteoporosis in postmenopausal 
women.
Table 2  Multiple linear regression analysis for the association 
between bone mineral density (BMD) and IgG seropositivities 
against C. pneumoniae or H. pylori in the cross-sectional and pro-
spective phases of the study
BMD bone mineral density, BMI body mass index
Femoral neck 
BMD
Lumbar 
BMD
β P β P
Cross-sectional analysis
 Chlamydia pneumoniae
  Unadjusted −0.03 0.534 0.02 0.728
  Age-, and BMI-adjusted −0.01 0.747 0.04 0.338
 Helicobacter pylori
  Unadjusted 0.12 0.046 0.09 0.139
  Age-adjusted, and BMI- 
adjusted
0.07 0.135 0.04 0.385
Prospective analysis
 Chlamydia pneumoniae
  Unadjusted −0.01 0.82 0.06 0.403
  Age-adjusted, and BMI-adjusted 0.02 0.699 0.06 0.399
 Helicobacter pylori
  Unadjusted 0.19 0.03 0.06 0.419
  Age-adjusted, and BMI-adjusted 0.13 0.055 0.05 0.514
Table 3  Prediction of osteoporosis by IgG seropositivities against C. pneumoniae or H. pylori using multivariable odds ratios (OR), relative risk 
(RR) and their 95 % confidence intervals (CI)
OR 95 % CI P value
Cross-sectional analysis
 Chlamydia pneumoniae 1.16 0.37–3.50 0.796
 Helicobacter pylori 1.02 0.39–2.55 0.997
RR 95 % CI P value
Prospective analysis
 Chlamydia pneumoniae 1.12 0.52–2.38 0.766
 Helicobacter pylori 0.965 0.51–1.80 0.910
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For the first time, Bailey et al. [3] demonstrated gen-
eralized bone loss associated with increased IL-6, IL-1, 
and T-cells that expressed RANKL due to C. pneumoniae 
infection in mice. They suggested a causal linkage between 
C. pneumoniae and bone loss following their in vitro study, 
which showed similar bone resorptive cytokine profiles as 
those in vivo in a C. pneumoniae-infected osteoblast cell 
line [3].
Rizzo et al. [4] showed that C. pneumoniae was able to 
invade and survive within an SaOS-2 osteoblastic cell line. 
They also suggested a pathological role of C. pneumoniae 
in generalized bone loss following their observation that 
infected osteoblasts produced increased levels of proin-
flammatory cytokines and chemokines [4].
Very recently, Di Pietro et al. [5] evaluated 32 women 
with osteoporosis and 27 with osteoarthritis who under-
went hip joint replacement surgery for femoral neck frac-
ture to determine whether C. pneumoniae infection is a 
risk factor for osteoporosis-associated bone loss. They 
found chlamydial DNA in osteoporotic bone tissue but 
not in non-osteoporotic bone tissue [5]. In addition, they 
detected a significant association between the presence of 
C. pneumoniae DNA, both in bone tissue and in peripheral 
blood mononuclear cells of osteoporotic women, and an 
increase in the sRANKL/OPG ratio and circulating resorp-
tive cytokines [5]. Hence, Di Pietro et al. [5] considered C. 
pneumoniae infection as a new risk factor for osteoporosis-
associated bone loss.
In contrast to the aforementioned in vitro and in vivo 
studies, which illustrated the contribution of C. pneumo-
niae infection to bone loss, we found no significant asso-
ciation between seropositivity to C. pneumoniae and BMD 
in postmenopausal women. In the prospective phase of our 
study, we did not detect a significant association between 
seropositivity for C. pneumoniae at baseline and changes in 
BMD and incident osteoporosis in postmenopausal women. 
Undoubtedly, the current study does not rule out a possi-
ble causal link between C. pneumoniae and osteoporosis-
associated bone loss. However, it suggests that serological 
markers of C. pneumoniae infection may be ineffective in 
detecting any relationship between C. pneumoniae infec-
tion and BMD, if such a relationship exists.
Likewise, the correlation of serology and the polymer-
ase chain reaction for detection of vascular C. pneumoniae 
infection in coronary artery disease patients was poor [14]. 
In a prospective study and meta-analysis, IgA and IgG C. 
pneumoniae titers were not strongly predictive of coro-
nary heart disease in the general population [15]. However, 
accumulating evidence suggests that C. pneumoniae is an 
important contributory factor in the pathogenesis of athero-
sclerosis, from the initial stage of the inflammatory lesions 
to plaque rupture [1].
According to the results of the current study and discrep-
ancies between seroepidemiological studies and polymer-
ase chain reaction (PCR)-based investigations for detection 
of vascular C. pneumoniae infection in coronary artery 
disease patients [14, 15], serological markers appear not to 
be a predictive tool for individual vascular C. pneumoniae 
infection or osteoporosis-associated bone loss.
Gastric inflammation in patients infected with H. pylori 
has been characterized by increased activity of Th1 and 
Th17 that mediate a proinflammatory response toward 
clearance of H. pylori infection and increased production 
of IL-1, IL-6, IL-12, IL-18, IL-23, TNF-alpha, and IFN-
gamma [16, 17]. This proinflammatory response and the 
release of inflammatory cytokines in H. pylori infection 
may indicate a plausible role for this organism in bone 
resorption. However, only 4 studies in the medical literature 
investigated H. pylori infection in relation to bone health, 
all of which reported contradictory findings [8–11]. In con-
trast to a case–control study that reported a higher preva-
lence of CagA-positive strains in osteoporotic men, two 
studies with small samples of women showed that H. pylori 
infection with or without chronic atrophic gastritis in post-
menopausal women [11] and H. pylori associated gastritis 
in women [10] were not associated with decreased BMD. 
Consistent with the results of these studies in women [10, 
11], we also found no association between IgG seropositiv-
ity with H. pylori and BMD/BMD loss in postmenopausal 
women. Therefore, H. pylori infection does not seem to be 
an important risk factor for bone loss in women.
Similar to the findings of a study in children that found 
that H. pylori infection was not accompanied by signifi-
cant changes in circulating estradiol, parathyroid hormone, 
cross-linked collagen I carboxy terminal telopeptide, bone-
specific alkaline phosphatase, N-terminal cross-links of 
human pro-collagen type I, N-mid-osteocalcin, calcium, 
and phosphate [8], we did not find significant differences in 
bone turnover markers between IgG H. pylori positive and 
IgG H. pylori negative postmenopausal women.
A balance in RNKL and OPG is essential for osteoclast 
function and bone remodeling [18]. In the current study, 
we found a significant difference in OPG between IgG H. 
pylori positive and IgG H. pylori negative postmenopausal 
women, but this significant difference was lost by further 
adjustment for age. Circulating levels of RANKL and OPG 
also did not differ significantly between IgG C. pneumoniae 
positive and IgG C. pneumoniae negative postmenopausal 
women. Previously, we showed that circulating levels of 
RANKL/OPG in the osteoimmunity system are associated 
with BMD in postmenopausal women [19]. The observed 
lack of a relationship between H. pylori or C. pneumoniae 
IgG seropositivities and the RANKL/OPG osteoimmunity 
system may be a clue to explain the findings of the current 
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study, which showed that neither H. pylori nor C. pneumo-
niae is involved in postmenopausal bone loss.
We acknowledge several limitations. Although this 
study is the first population-based study to investigate a 
link between C. pneumoniae seropositivity and BMD, 
its findings should be confirmed in further human stud-
ies with larger samples. We did not measure IgA or IgM 
titers for C. pneumoniae infection. However, currently, 
there is no valid marker to show the presence of chronic 
C. pneumoniae infection in seroepidemiological studies 
[1]. In addition, it has been reported that there is a sig-
nificant relationship between organism-specific DNA or 
antigens in coronary arteries obtained at autopsy and lev-
els of pre-existing C. pneumoniae-specific IgG antibody 
titers but not IgA or IgM titers [20]. Furthermore, the 
measurement of additional inflammatory markers, pro-
inflammatory cytokines, and chemokines that are indica-
tors of bone resorption merits consideration to elucidate 
the complex system that regulates chronic infection, the 
immune system, and bone resorption. We used seroposi-
tivity as a marker of infection. Although it has the advan-
tage of clinical applicability, the assessment of infection 
status based on serology without further clinical or labo-
ratory characterization is subject to diagnostic inaccura-
cies, especially if seropositivity is common because of 
the widespread distribution of the incriminated microor-
ganism. Since we did not measure IgG seropositivity for 
the studied microorganisms at the follow-up period, new 
seroconversions indicating recent infections with C. pneu-
moniae or H. pylori could not be reflected in the current 
study. This limitation may be a pitfall for interpretation of 
the findings.
In conclusion, neither C. pneumoniae nor H. pylori IgG 
seropositivity was associated with baseline bone turno-
ver markers, OPG, sRANKL, the sRANKL/OPG ratio, 
and BMD at any skeletal sites and bone loss at 5.8-year 
follow-up in postmenopausal women. In addition, chronic 
infection with C. pneumoniae or H. pylori did not predict 
incident osteoporosis among the women. However, this 
lack of predictive power of IgG seropositivities against C. 
pneumoniae and H. pylori for osteoporosis-associated bone 
loss should not be interpreted as these organisms have no 
contributory role in postmenopausal osteoporosis. Further 
investigations in human studies are warranted to illustrate 
any possible causal role of chronic infection with C. pneu-
moniae and H. pylori in postmenopausal osteoporosis.
Acknowledgments This project was supported jointly by a grant 
from Bushehr University of Medical Sciences and Health Services; 
the Ministry of Health; Tehran Endocrine Research Center; Tehran 
University of Medical Science, Tehran, Islamic Republic of Iran; and 
Bushehr Province Research Committee (PGHRC: 1385.234.345). 
The authors thank Dr. Syed Reza Imami, Shiva Mosadeghzadeh, and 
Zahra Amiri for assistance in the field work.
Conflict of interest An award was given to Iraj Nabipour by “Novo 
Nordisk Pars” (The Best Innovator of Diabetes in Iran 2013). All 
other authors have no conflicts of interest.
References
 1. Watson C, Alp NJ (2008) Role of Chlamydia pneumoniae in ath-
erosclerosis. Clin Sci (Lond) 114:509–531
 2. Campbell LA, Kuo CC (2002) Chlamydia pneumoniae patho-
genesis. J Med Microbiol 51:623–625
 3. Bailey L, Engstrom P, Nordstrom A, Bergstrom S, Waldenstrom 
A, Nordstrom P (2008) Chlamydia pneumoniae infection results 
in generalized bone loss in mice. Microbes Infect 10:1175–1181
 4. Rizzo A, Di Domenico M, Carratelli CR, Mazzola N, Paolillo R 
(2011) Induction of proinflammatory cytokines in human osteo-
blastic cells by Chlamydia pneumoniae. Cytokine 56:450–457
 5. Di Pietro M, Schiavoni G, Sessa V, Pallotta F, Costanzo G, Sessa 
R (2013) Chlamydia pneumoniae and osteoporosis-associated 
bone loss: a new risk factor? Osteoporos Int 24:1677–1682
 6. Gasbarrini A, Franceschi F, Armuzzi A, Ojetti V, Candelli M, 
Torre ES, De Lorenzo A, Anti M, Pretolani S, Gasbarrini G 
(1999) Extradigestive manifestations of Helicobacter pylori gas-
tric infection. Gut 45(Suppl 1):I9–I12
 7. Papamichael KX, Papaioannou G, Karga H, Roussos A, Mant-
zaris GJ (2009) Helicobacter pylori infection and endocrine dis-
orders: is there a link? World J Gastroenterol 15:2701–2707
 8. Ozdem S, Akcam M, Yilmaz A, Gultekin M, Artan R (2007) Bio-
chemical markers of bone metabolism in children with Helico-
bacter pylori infection. Dig Dis Sci 52:967–972
 9. Figura N, Gennari L, Merlotti D, Lenzi C, Campagna S, Franci 
B, Lucani B, Trabalzini L, Bianciardi L, Gonnelli C, Santucci A, 
Nut A (2005) Prevalence of Helicobacter pylori infection in male 
patients with osteoporosis and controls. Dig Dis Sci 50:847–852
 10. Kakehasi AM, Rodrigues CB, Carvalho AV, Barbosa AJ (2009) 
Chronic gastritis and bone mineral density in women. Dig Dis 
Sci 54:819–824
 11. Kakehasi AM, Mendes CM, Coelho LG, Castro LP, Barbosa AJ 
(2007) The presence of Helicobacter pylori in postmenopausal 
women is not a factor to the decrease of bone mineral density. 
Arq Gastroenterol 44:266–270
 12. Tohidi M, Akbarzadeh S, Larijani B, Kalantarhormozi M, Osto-
var A, Assadi M, Vahdat K, Farrokhnia M, Sanjdideh Z, Amirine-
jad R, Nabipour I (2012) Omentin-1, visfatin and adiponectin 
levels in relation to bone mineral density in Iranian postmeno-
pausal women. Bone 51:876–881
 13. World Health Organization (1994) Assessment of fracture risk 
and its application to screening for postmenopausal osteoporosis. 
Report of a WHO Study Group. World Health Organ Tech Rep 
Ser 843:1–129
 14. Maass M, Gieffers J, Krause E, Engel PM, Bartels C, Solbach 
W (1998) Poor correlation between microimmunofluorescence 
serology and polymerase chain reaction for detection of vascu-
lar Chlamydia pneumoniae infection in coronary artery disease 
patients. Med Microbiol Immunol 187:103–106
 15. Danesh J, Whincup P, Lewington S, Walker M, Lennon L, Thom-
son A, Wong YK, Zhou X, Ward M (2002) Chlamydia pneumo-
niae IgA titres and coronary heart disease; prospective study and 
meta-analysis. Eur Heart J 23:371–375
 16. Al-Sammak F, Kalinski T, Weinert S, Link A, Wex T, Mal-
fertheiner P (2013) Gastric epithelial expression of IL-12 
cytokine family in Helicobacter pylori infection in human: is it 
head or tail of the coin? PLoS One 8:e75192
 17. Romero-Adrian TB, Leal-Montiel J, Monsalve-Castillo F, Men-
gual-Moreno E, McGregor EG, Perini L, Antunez A (2010) 
428 J Bone Miner Metab (2016) 34:422–428
1 3
Helicobacter pylori: bacterial factors and the role of cytokines in 
the immune response. Curr Microbiol 60:143–155
 18. Hofbauer LC, Kuhne CA, Viereck V (2004) The OPG/RANKL/
RANK system in metabolic bone diseases. J Musculoskelet Neu-
ronal Interact 4:268–275
 19. Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, 
Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi 
N, Amiri Z (2009) Relationships among serum receptor of 
nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity 
C-reactive protein, and bone mineral density in postmenopausal 
women: osteoimmunity versus osteoinflammatory. Menopause 
16:950–955
 20. Davidson M, Kuo CC, Middaugh JP, Campbell LA, Wang SP, 
Newman WP 3rd, Finley JC, Grayston JT (1998) Confirmed 
previous infection with Chlamydia pneumoniae (TWAR) and 
its presence in early coronary atherosclerosis. Circulation 
98:628–633
